The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 05, 2019

Filed:

Jun. 05, 2017
Applicant:

Ariagen, Inc., Menlo Park, CA (US);

Inventor:

Jiasheng Song, Madison, WI (US);

Assignee:

Ariagen, Inc., Menlo Park, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/427 (2006.01); A61P 35/00 (2006.01); A61K 31/40 (2006.01); A61K 31/425 (2006.01); A61K 31/475 (2006.01); A61K 45/06 (2006.01); C07D 417/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/427 (2013.01); A61K 31/40 (2013.01); A61K 31/425 (2013.01); A61K 31/475 (2013.01); A61K 45/06 (2013.01); C07D 417/06 (2013.01);
Abstract

A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.


Find Patent Forward Citations

Loading…